Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: review of randomised controlled trials from 1997 to 2017

Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: review of randomised controlled trials from 1997 to 2017

Objective: To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. <br/> Methods: There were 382 trials of hip and/or knee OA identified from the Cl...

Full description

Bibliographic Details
Main Authors: Smith, T, Mansfield, M, Hawker, G, Hunter, D, March, L, Boers, M, Shea, B, Christensen, R, Guillemin, F, Terwee, C, Williamson, P, Roos, E, Loeser, R, Schnitzer, T, Kloppenburg, M, Neogi, T, Ladel, C, Kalsi, G, Kaiser, U, Buttel, T, Ashford, A, Mobasheri, A, Arden, N, Tennant, A, Hochberg, M, De Wit, M, Tugwell, P, Conaghan, P
Format: Journal article
Language:English
Published: Journal of Rheumatology 2019
Description
Summary:Objective: To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. <br/> Methods: There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases. <br/> Results: COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain. <br/> Conclusion: Limited adoption of the COS domains indicates that further consideration to improve uptake is required.

Similar Items